3 terminated, 2 active not recruiting, 2 completed, 1 recruiting. 7 Phase 2, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Terminated 3, Active not recruiting 2, Completed 1, Withdrawn 1 |
| Not applicable | 1 | Completed 1 |
| Phase 1 | 1 | Suspended 1 |
Follow Hematologic and Lymphocytic Disorder: new trials by email Literature Review of Hematologic and Lymphocytic Disorder trials Research Report on Hematologic and Lymphocytic Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation Biopsy, Biospecimen Collection, Chimeric Antigen Receptor T-Cell Therapy - Chronic Graft Versus Host Disease, Hematologic and Lymphocytic Disorder | Phase 1 | Suspended | City of Hope Medical Center | 27 | 2024-02-19 | 2025-11-13 |
| Itacitinib for the Prevention of Graft Versus Host Disease Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Cyclophosphamide - Hematologic and Lymphocytic Disorder | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 31 | 2022-01-11 | 2026-10-07 |
| Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration - Hematologic and Lymphocytic Disorder, Hematopoietic and Lymphoid System Neoplasm | Phase 2 | Active not recruiting | Fred Hutchinson Cancer Center | 116 | 2021-05-14 | 2026-01-02 |
| Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation Fludarabine, Itacitinib Adipate, Melphalan - Acute Leukemia, Hematologic and Lymphocytic Disorder | Phase 2 | Completed | City of Hope Medical Center | 59 | 2020-11-05 | 2026-11-03 |
| Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Fludarabine - Allogeneic Stem Cell Transplant Recipient, Hematologic and Lymphocytic Disorder | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2020-09-22 | 2020-10-29 | |
| AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission Azacitidine, Venetoclax - Acute Myeloid Leukemia in Remission, FLT3 Gene Mutation | Phase 2 | Terminated | M.D. Anderson Cancer Center | 36 | 2019-09-13 | 2026-10-16 |
| Parenting Skills Intervention in Improving Medication Adherence in Pediatric Cancer Patients Educational Activity, Patient Monitoring, Questionnaire Administration - Guardian, Hematologic and Lymphocytic Disorder | Not applicable | Completed | Roswell Park Cancer Institute | 9 | 2019-01-03 | 2021-09-16 |
| Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 150 | 2017-09-11 | 2026-05-14 |
| Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia Platelet Transfusion - Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 4 | 2017-06-09 | 2019-10-21 |
| Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers Biospecimen Collection, Laboratory Biomarker Analysis, Questionnaire Administration - Healthy Subject, Hematologic and Lymphocytic Disorder | Recruiting | University of Southern California | 625 | 2017-04-12 | 2026-04-02 |
Hematologic Diseases (10) · Leukemia, Myeloid, Acute (3) · Myelodysplastic Syndromes (3) · Hematologic Neoplasms (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Neoplasms (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Primary Myelofibrosis (2) · Blastic Plasmacytoid Dendritic Cell Neoplasm (1) · Bronchiolitis Obliterans Syndrome (1) · Hodgkin Disease (1) · Immune System Diseases (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Prolymphocytic (1)
Hemic and Lymphatic Diseases (10) · Neoplasms (4) · Bone Marrow Diseases (3) · Immune System Diseases (3) · Leukemia (3) · Leukemia, Myeloid (3) · Myeloproliferative Disorders (3) · Neoplasms by Histologic Type (3) · Neoplasms by Site (3) · Cardiovascular Diseases (2) · Chronic Disease (2) · Disease Attributes (2) · Immunoproliferative Disorders (2) · Leukemia, B-Cell (2) · Leukemia, Lymphoid (2)
Tacrolimus (3) · fludarabine (3) · Busulfan (2) · Cyclophosphamide (2) · Disulfides (2) · INCB039110 (2) · Sirolimus (2) · itacitinib (2) · Azacitidine (1) · Biopsy (1) · Cyclosporine (1) · Cyclosporins (1) · Immunoglobulin G (1) · Immunoglobulins (1) · Immunotherapy, Adoptive (1)
Fred Hutchinson Cancer Center (3) · M.D. Anderson Cancer Center (3) · City of Hope Medical Center (2) · Roswell Park Cancer Institute (1) · University of Southern California (1)
United States (10)
Amandeep Salhotra (1) · Casey O'Connell, MD (1) · David Garcia (1) · Elizabeth Bouchard (1) · Haris Ali (1) · Masumi Ueda Oshima (1) · Stephanie J. Lee (1) · Tapan M Kadia (1) · Uday R Popat (1) · Uday R Popat, MD (1)
P30CA015704 (2), P01CA078902 (1), P30CA014089 (1), P30CA033572 (1)